Filing Flows › bioAffinity Technologies (BIAF) › Q3 2025
bioAffinity Technologies (BIAF) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
bioAffinity Technologies (BIAF) reported revenue of $1.4M for the third quarter 2025 (Q3 2025), -38% from a year earlier and +14% from the quarter before. Operating margin was -158.6%, net loss $5.1M (349.3% of revenue).
bioAffinity Technologies, Q3 2025: revenue $1.4M (-38% year over year), operating margin -158.6%, net loss $5.1M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | +14% | -38% |
| Operating profit | −$2.3M | — | — |
| Net earnings | −$5.1M | — | — |
| Operating cash flow | −$2.5M | — | — |
What changed
Revenue was $1.4M in Q3 2025, down 38% year over year and up 14% from the previous quarter. Health Care, Patient Service was the largest line at 81% of revenue. Health Care, Patient Service lost $877K year over year (down 43%), 97% of the total change.
Operating costs exceeded revenue by $2.3M, an operating margin of -158.6%. Total costs fell 14% while revenue fell 38%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $5.1M, wider than the previous quarter's $4.1M loss. Net interest and other expense of $2.8M was the main reason.
Operating cash flow was −$2.5M. Non-cash charges added back $113K of depreciation and amortization and $67K of share-based compensation. Working capital and other items added $2.4M. Capital expenditures of −$4K exceeded it, leaving free cash flow of −$2.5M.
Questions
What was bioAffinity Technologies' revenue in the third quarter 2025?
bioAffinity Technologies (BIAF) reported revenue of $1.4M for the third quarter 2025 (Q3 2025), -38% from a year earlier and +14% from the quarter before.
Was bioAffinity Technologies profitable in the third quarter 2025?
Operating loss was $2.3M (-158.6% of revenue) and net loss $5.1M.